Company Overview of Parion Sciences, Inc.
Parion Sciences, Inc., a pharmaceutical company, engages in the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The company primarily focuses on developing therapeutic agents for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disorder, and bronchiectasis. It develops epithelial sodium channel blockers that are used for the treatment of diseases associated with lung, mouth, nose, and the gastrointestinal tract. The company also develops an oral rinse for the relief of chronic dry mouth; and compounds for patients suffering from dry eyes. It was formerly known as CYFI, Inc. and changed its name to Parion Sciences, In...
2800 Meridian Parkway
Durham, NC 27713
Founded in 1999
Key Executives for Parion Sciences, Inc.
Co-Founder, Co-Chairman and Chief Executive Officer
Co-Founder and Co-Chairman
Senior Director of Clinical & Regulatory Operations
Compensation as of Fiscal Year 2014.
Parion Sciences, Inc. Key Developments
Parion Sciences, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015
Feb 18 15
Parion Sciences, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.
Parion Sciences Announces Exclusive Option Agreement for the Development and Commercialization of P-321 in Ophthalmology in Certain Asian Territories
Jun 12 14
Parion Sciences, Inc. announced that Parion and Santen Pharmaceutical Co. Ltd. have entered into the "OPTION, LICENSE AND DEVELOPMENT AGREEMENT", an exclusive option agreement for the development and commercialization of P-321 for dry eye disease in certain Asian territories. On May 1, 2014 Parion announced FDA Acceptance of the Investigational New Drug Application for clinical testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease. Parion plans to initiate a Phase 1/2a clinical trial in patients suffering from dry eye disease in July, 2014 in the United States. Under the terms of agreement, Santen will make an undisclosed option payment to secure certain rights to P-321 and to support the upcoming Phase 1/2a clinical trial. Should Santen elect to exercise their option, Santen will have responsibility for all clinical, regulatory, and commercial activity for the ophthalmic use of P-321 in the agreed Asian territories. Parion retains all rights to develop and commercialize P-321 in the rest of the world, including North America and Europe.
Parion Sciences Announces Executive Changes
Jun 2 14
Parion Sciences announced senior leadership and organizational changes. The changes include the following: Paul Boucher has been promoted to President and will lead the executive management team, business development and provide overall corporate direction. Paul previously served as Vice-President of Finance & Business at Parion. Joe Schachle has been appointed as Chief Operating Officer (COO) and will be responsible for corporate strategy, commercial operations, and corporate operations. Joe joined Parion from Grifols where he served as Head of Global Marketing Operations. Anita Woodring has been appointed as Senior Director of Clinical & Regulatory Operations. Anita is joining Parion from Research Triangle Institute (RTI) where she served as Regulatory Project Leader. These changes are intended to support the growth plans for the organization based on the initiation of trials across 3 clinical programs and increased efforts in early stage research projects.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|